Remicade biosim floats through EU approval
This article was originally published in Scrip
Executive Summary
The European Commission has given Hospira/Celltrion's version of J&J/Merck & Co's anti-TNF monoclonal antibody Remicade (infliximab) the formal green light after what seems to have been a very smooth approval process.
You may also be interested in...
Biosimilars: A Decade In Review
The past decade has been transformative for the global biosimilars industry as regulators, developers, physicians, patients and payers from all over the world have grappled with complex, and often market-shaping, issues.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.